Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Bacterial mutagenicity screening in the pharmaceutical industry.

Escobar PA, Kemper RA, Tarca J, Nicolette J, Kenyon M, Glowienke S, Sawant SG, Christensen J, Johnson TE, McKnight C, Ward G, Galloway SM, Custer L, Gocke E, O'Donovan MR, Braun K, Snyder RD, Mahadevan B.

Mutat Res. 2013 Apr-Jun;752(2):99-118. doi: 10.1016/j.mrrev.2012.12.002. Epub 2012 Dec 20. Erratum in: Mutat Res. 2013 Oct-Dec;753(2):155.

PMID:
23262374
[PubMed - in process]
2.

How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop.

Kirkland D, Pfuhler S, Tweats D, Aardema M, Corvi R, Darroudi F, Elhajouji A, Glatt H, Hastwell P, Hayashi M, Kasper P, Kirchner S, Lynch A, Marzin D, Maurici D, Meunier JR, Müller L, Nohynek G, Parry J, Parry E, Thybaud V, Tice R, van Benthem J, Vanparys P, White P.

Mutat Res. 2007 Mar 30;628(1):31-55. Epub 2007 Jan 13.

PMID:
17293159
[PubMed - indexed for MEDLINE]
3.

Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.

Thybaud V, Aardema M, Clements J, Dearfield K, Galloway S, Hayashi M, Jacobson-Kram D, Kirkland D, MacGregor JT, Marzin D, Ohyama W, Schuler M, Suzuki H, Zeiger E; Expert Working Group on Hazard Identification and Risk Assessment in Relation to In Vitro Testing.

Mutat Res. 2007 Feb 3;627(1):41-58. Epub 2006 Nov 27.

PMID:
17126066
[PubMed - indexed for MEDLINE]
4.

Genotoxicity testing: current practices and strategies used by the pharmaceutical industry.

Purves D, Harvey C, Tweats D, Lumley CE.

Mutagenesis. 1995 Jul;10(4):297-312.

PMID:
7476265
[PubMed - indexed for MEDLINE]
5.

Use of the Miniscreen assay to screen novel compounds for bacterial mutagenicity in the pharmaceutical industry.

Burke DA, Wedd DJ, Burlinson B.

Mutagenesis. 1996 Mar;11(2):201-5.

PMID:
8671739
[PubMed - indexed for MEDLINE]
Free Article
6.

The role of genetic toxicology in drug discovery and optimization.

Custer LL, Sweder KS.

Curr Drug Metab. 2008 Nov;9(9):978-85. Review.

PMID:
18991595
[PubMed - indexed for MEDLINE]
7.

Evaluation of the Vitotox and RadarScreen assays for the rapid assessment of genotoxicity in the early research phase of drug development.

Westerink WM, Stevenson JC, Lauwers A, Griffioen G, Horbach GJ, Schoonen WG.

Mutat Res. 2009 May 31;676(1-2):113-30. doi: 10.1016/j.mrgentox.2009.04.008. Epub 2009 Apr 22.

PMID:
19393335
[PubMed - indexed for MEDLINE]
8.

The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.

Amacher DE.

Toxicol Appl Pharmacol. 2010 May 15;245(1):134-42. doi: 10.1016/j.taap.2010.02.011. Epub 2010 Feb 26. Review.

PMID:
20219512
[PubMed - indexed for MEDLINE]
9.

Practical aspects of mutagenicity testing strategy: an industrial perspective.

Gollapudi BB, Krishna G.

Mutat Res. 2000 Nov 20;455(1-2):21-8. Review.

PMID:
11113465
[PubMed - indexed for MEDLINE]
10.
11.

Alternative strategies in drug development: clinical pharmacological aspects.

Kuhlmann J.

Int J Clin Pharmacol Ther. 1999 Dec;37(12):575-83. Review.

PMID:
10599949
[PubMed - indexed for MEDLINE]
12.

Relevance and follow-up of positive results in in vitro genetic toxicity assays: an ILSI-HESI initiative.

Thybaud V, Aardema M, Casciano D, Dellarco V, Embry MR, Gollapudi BB, Hayashi M, Holsapple MP, Jacobson-Kram D, Kasper P, MacGregor JT, Rees R.

Mutat Res. 2007 Oct 4;633(2):67-79. Epub 2007 May 24.

PMID:
17616430
[PubMed - indexed for MEDLINE]
13.

Reduction of use of animals in regulatory genotoxicity testing: Identification and implementation opportunities-Report from an ECVAM workshop.

Pfuhler S, Kirkland D, Kasper P, Hayashi M, Vanparys P, Carmichael P, Dertinger S, Eastmond D, Elhajouji A, Krul C, Rothfuss A, Schoening G, Smith A, Speit G, Thomas C, van Benthem J, Corvi R.

Mutat Res. 2009 Nov-Dec;680(1-2):31-42. doi: 10.1016/j.mrgentox.2009.09.002. Epub 2009 Sep 16.

PMID:
19765670
[PubMed - indexed for MEDLINE]
14.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
[PubMed - indexed for MEDLINE]
15.

Comparison of the results of a modified miniscreen and the standard bacterial reverse mutation assays.

Diehl MS, Willaby SL, Snyder RD.

Environ Mol Mutagen. 2000;36(1):72-7.

PMID:
10918362
[PubMed - indexed for MEDLINE]
16.

Mouse-specific carcinogens: an assessment of hazard and significance for validation of short-term carcinogenicity bioassays in transgenic mice.

Battershill JM, Fielder RJ.

Hum Exp Toxicol. 1998 Apr;17(4):193-205. Review.

PMID:
9617631
[PubMed - indexed for MEDLINE]
17.

Genotoxicity of nanomaterials: refining strategies and tests for hazard identification.

Pfuhler S, Elespuru R, Aardema MJ, Doak SH, Maria Donner E, Honma M, Kirsch-Volders M, Landsiedel R, Manjanatha M, Singer T, Kim JH.

Environ Mol Mutagen. 2013 May;54(4):229-39. doi: 10.1002/em.21770. Epub 2013 Mar 21.

PMID:
23519787
[PubMed - indexed for MEDLINE]
18.

Drug Discovery and Development for Pain.

Chaplan SR, Eckert III WA, Carruthers NI.

In: Kruger L, Light AR, editors. Translational Pain Research: From Mouse to Man. Boca Raton, FL: CRC Press; 2010. Chapter 18.

PMID:
21882460
[PubMed]
Books & Documents
19.

Testing strategies in mutagenicity and genetic toxicology: an appraisal of the guidelines of the European Scientific Committee for Cosmetics and Non-Food Products for the evaluation of hair dyes.

Kirkland DJ, Henderson L, Marzin D, Müller L, Parry JM, Speit G, Tweats DJ, Williams GM.

Mutat Res. 2005 Dec 30;588(2):88-105. Epub 2005 Dec 2. Review.

PMID:
16326131
[PubMed - indexed for MEDLINE]
20.

Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.

Singh SS.

Curr Drug Metab. 2006 Feb;7(2):165-82. Review.

PMID:
16472106
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk